Cortex Discovery is a German AI drug discovery company positioned as a prediction and screening platform for the preclinical R&D stage. Its core offering is not a general-purpose conversational AI, but a deep-learning foundation model for small-molecule drug discovery, designed to screen large chemical spaces and identify candidate compounds that are more likely to proceed to experimental validation.
According to the website, its model is trained on 2.5 million molecules and 750 million biological experiment data points. It can simultaneously predict therapeutic effects, off-target effects, and pharmacological properties, while covering complex biochemical interactions such as protein affinity and pathway activation/inhibition. Services include virtual high-throughput screening, ADMET prediction, off-target screening, hit analogs and de novo molecule generation, as well as integrated services from hit discovery to lead optimization. The company is also developing AI-assisted molecular docking, claiming that its prototype can handle detailed force fields and flexible targets and is 1000 times faster than existing open-source and commercial alternatives; however, this claim lacks publicly available benchmark details.
The website does not list standard pricing, subscription plans, or a free trial. Its business model appears to be primarily service-based and milestone-driven, and the company is also seeking private or academic laboratories to perform in vitro validation of compounds discovered in silico. As such, it is more of a professional B2B research collaboration service than a self-service SaaS tool.
Its strengths lie in covering key parts of the drug discovery workflow, including efficacy, ADMET, off-target effects, and molecular optimization. The company also discloses independent lab validation cases, such as repurposed drugs against SARS-CoV-2, HIV1 inhibitors, cancer growth inhibitors, and an NRF2 agonist screen of 23 million compounds in which 3 of 7 tested compounds were confirmed active. Limitations include the lack of systematic public performance metrics, API information, delivery workflow details, and pricing transparency. Chinese-language support is also not disclosed.
Cortex Discovery is suitable for pharmaceutical companies, biotech firms, computational chemistry teams, and academic laboratories working on early-stage screening, lead optimization, and longevity medicine research. The website does not provide evidence regarding access from China, so this remains unknown; supported payment methods are also not disclosed. If localization or a more mature commercial ecosystem is required, comparable options include SchrΓΆdinger, Insilico Medicine, Atomwise, and Exscientia.
β This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on cortexdiscovery.com official site.
cortexdiscovery.com is an United States AI Apps provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach cortexdiscovery.com directly.